Neo-Bioscore 在指导接受新辅助化疗的三阴性乳腺癌患者术后治疗中的作用。
Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy.
机构信息
Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Department of Breast Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
出版信息
In Vivo. 2021 Mar-Apr;35(2):1041-1049. doi: 10.21873/invivo.12348.
AIM
Patients with triple-negative breast cancer (TNBC) who have not achieved pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) were considered for adjuvant capecitabine. This study was to explore the utility of the Neo-Bioscore in guiding post-surgical therapy in TNBC.
PATIENTS AND METHODS
The Neo-Bioscore was calculated for patients with non-metastatic primary breast cancer who received NAC at National Cancer Center Hospital East, Japan.
RESULTS
A total of 329 patients were evaluated. The Neo-Bioscore stratified prognosis after NAC better than clinical or pathological stage. The Neo-Bioscore performed well in the selection of patients with TNBC with excellent prognoses despite non-pCR; no death was observed in patients who had a Neo-Bioscore of 2, the lowest score in those with TNBC.
CONCLUSION
The Neo-Bioscore can improve the prognostic stratification of patients after NAC for breast cancer over clinical and pathological staging and may enable the identification of patients with non-pCR TNBC who can avoid additional adjuvant chemotherapy.
目的
新辅助化疗（NAC）后未达到病理完全缓解（pCR）的三阴性乳腺癌（TNBC）患者被考虑接受辅助卡培他滨治疗。本研究旨在探讨 Neo-Bioscore 在指导 TNBC 术后治疗中的应用。
患者和方法
在日本国家癌症中心医院东院接受 NAC 的非转移性原发性乳腺癌患者计算了 Neo-Bioscore。
结果
共评估了 329 名患者。Neo-Bioscore 比临床或病理分期更好地分层了 NAC 后的预后。Neo-Bioscore 在选择非 pCR 但预后良好的 TNBC 患者方面表现良好；在 TNBC 中得分最低的 2 分的患者中，没有观察到死亡。
结论
Neo-Bioscore 可改善乳腺癌 NAC 后患者的预后分层，优于临床和病理分期，可能有助于识别非 pCR TNBC 患者，使这些患者避免接受额外的辅助化疗。
Zotero 插件